We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal
Read MoreHide Full Article
Key Takeaways
GE HealthCare will acquire SOFIE Biosciences for $945M, with closing expected in the first half of 2027.
SOFIE adds 15 U.S. CMO sites and 21 cyclotrons, strengthening GEHC's PET manufacturing and distribution.
GEHC expects the deal to boost revenue growth, Adjusted EBIT margin and Adjusted EPS in its first full year.
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced a definitive agreement to acquire SOFIE Biosciences, a U.S.-based contract manufacturing organization (CMO) specializing in PET radiopharmaceuticals, for $945 million in cash. The acquisition is expected to establish a “final mile” footprint for PET radiopharmaceutical supply in the United States and expand GE HealthCare’s presence in the growing radiopharmaceutical market. The deal is expected to close in the first half of 2027, subject to regulatory approvals.
Per management, the PET radiopharmaceutical market is witnessing strong growth, supported by innovative radiotracers, advances in precision care and the rising adoption of targeted therapies. SOFIE Biosciences is expected to grow in the low double digits, expanding GE HealthCare’s presence across the radiopharmaceutical value chain. GEHC plans to leverage its manufacturing expertise across the United States, Europe and Japan to expand SOFIE, strengthen supply reliability and improve patient access to next-generation precision care products, including its Flyrcado product.
GE HealthCare expects the acquisition to boost revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership.
GEHC Stock Trend Following the News
Following the announcement, GEHC stock gained 2.3% at yesterday’s close. Year to date, shares of the company have fallen 19.9% compared with the industry’s 22.4% decline. However, the S&P 500 has risen 13.1% in the same timeframe.
The acquisition could strengthen GEHC’s growth profile by expanding its exposure to the high-growth radiopharmaceutical market and adding a broader U.S. manufacturing and distribution network. SOFIE Biosciences acquisition could improve GE HealthCare’s ability to serve time-sensitive PET demand while creating additional opportunities across the theranostics value chain. An expanded manufacturing footprint could improve patient access while creating opportunities to support both GEHC’s proprietary products and those of other radiopharmaceutical developers.
GEHC currently has a market capitalization of $29.04 billion.
Image Source: Zacks Investment Research
More on the News
SOFIE Biosciences will add a significant U.S. manufacturing footprint to GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment. It brings a network of 15 CMO sites with 21 cyclotrons across the United States, along with a theranostics-focused CDMO facility. The network is expected to support patient access to PET radiopharmaceuticals, where the 110-minute half-life of F18 products makes timely manufacturing and distribution critical.
The acquisition also gives GE HealthCare greater exposure to the industry’s radiopharmaceutical pipeline, which includes about 20 PET radiotracers and more than 30 radiotherapeutics in development. The company will gain U.S. rights to SOFIE Biosciences’ FAPI-74, a Phase III PET radiotracer with pan-cancer imaging potential. GEHC already holds outside-of-U.S. rights for the candidate. The asset could boost GEHC’s presence in the fast-growing PET imaging market, with potential diagnostic and theranostic applications across oncologic and non-oncologic indications. FAPI has the potential to further expand an already fast-growing global PET imaging market.
GE HealthCare will continue developing its own F18 portfolio while working with SOFIE Biosciences and other CMO partners. SOFIE Biosciences will remain an independent manufacturing partner for its customers after closing.
Industry Prospects Favoring the Market
According to a report by Precedence Research, the global radiopharmaceuticals market is estimated at $8.28 billion in 2026 and is projected to witness a CAGR of 7.3% through 2035.
Factors like the rising cancer burden, increasing adoption of PET imaging and radioligand therapies, expanding clinical validation and guidelines, and a strong pipeline of novel therapies are expected to support market growth.
Other News
GE HealthCare recently advanced its portfolio across healthcare AI and imaging. The company launched CareIntellect for Operations, an AI-powered SaaS application that helps health systems anticipate capacity challenges up to 72 hours ahead, with Queen’s Health Systems and Duke Health as the first users. GEHC also submitted its next-generation StarGuide GX digital 4D CZT SPECT/CT system to the FDA for 510(k) clearance following its CE Mark. Its Photonova Spectra advanced photon-counting CT system received CE Mark, following FDA clearance and Japanese regulatory approval in March 2026.
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical Services (WST - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Shutterstock
GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced a definitive agreement to acquire SOFIE Biosciences, a U.S.-based contract manufacturing organization (CMO) specializing in PET radiopharmaceuticals, for $945 million in cash. The acquisition is expected to establish a “final mile” footprint for PET radiopharmaceutical supply in the United States and expand GE HealthCare’s presence in the growing radiopharmaceutical market. The deal is expected to close in the first half of 2027, subject to regulatory approvals.
Per management, the PET radiopharmaceutical market is witnessing strong growth, supported by innovative radiotracers, advances in precision care and the rising adoption of targeted therapies. SOFIE Biosciences is expected to grow in the low double digits, expanding GE HealthCare’s presence across the radiopharmaceutical value chain. GEHC plans to leverage its manufacturing expertise across the United States, Europe and Japan to expand SOFIE, strengthen supply reliability and improve patient access to next-generation precision care products, including its Flyrcado product.
GE HealthCare expects the acquisition to boost revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership.
GEHC Stock Trend Following the News
Following the announcement, GEHC stock gained 2.3% at yesterday’s close. Year to date, shares of the company have fallen 19.9% compared with the industry’s 22.4% decline. However, the S&P 500 has risen 13.1% in the same timeframe.
The acquisition could strengthen GEHC’s growth profile by expanding its exposure to the high-growth radiopharmaceutical market and adding a broader U.S. manufacturing and distribution network. SOFIE Biosciences acquisition could improve GE HealthCare’s ability to serve time-sensitive PET demand while creating additional opportunities across the theranostics value chain. An expanded manufacturing footprint could improve patient access while creating opportunities to support both GEHC’s proprietary products and those of other radiopharmaceutical developers.
GEHC currently has a market capitalization of $29.04 billion.
Image Source: Zacks Investment Research
More on the News
SOFIE Biosciences will add a significant U.S. manufacturing footprint to GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment. It brings a network of 15 CMO sites with 21 cyclotrons across the United States, along with a theranostics-focused CDMO facility. The network is expected to support patient access to PET radiopharmaceuticals, where the 110-minute half-life of F18 products makes timely manufacturing and distribution critical.
The acquisition also gives GE HealthCare greater exposure to the industry’s radiopharmaceutical pipeline, which includes about 20 PET radiotracers and more than 30 radiotherapeutics in development. The company will gain U.S. rights to SOFIE Biosciences’ FAPI-74, a Phase III PET radiotracer with pan-cancer imaging potential. GEHC already holds outside-of-U.S. rights for the candidate. The asset could boost GEHC’s presence in the fast-growing PET imaging market, with potential diagnostic and theranostic applications across oncologic and non-oncologic indications. FAPI has the potential to further expand an already fast-growing global PET imaging market.
GE HealthCare will continue developing its own F18 portfolio while working with SOFIE Biosciences and other CMO partners. SOFIE Biosciences will remain an independent manufacturing partner for its customers after closing.
Industry Prospects Favoring the Market
According to a report by Precedence Research, the global radiopharmaceuticals market is estimated at $8.28 billion in 2026 and is projected to witness a CAGR of 7.3% through 2035.
Factors like the rising cancer burden, increasing adoption of PET imaging and radioligand therapies, expanding clinical validation and guidelines, and a strong pipeline of novel therapies are expected to support market growth.
Other News
GE HealthCare recently advanced its portfolio across healthcare AI and imaging. The company launched CareIntellect for Operations, an AI-powered SaaS application that helps health systems anticipate capacity challenges up to 72 hours ahead, with Queen’s Health Systems and Duke Health as the first users. GEHC also submitted its next-generation StarGuide GX digital 4D CZT SPECT/CT system to the FDA for 510(k) clearance following its CE Mark. Its Photonova Spectra advanced photon-counting CT system received CE Mark, following FDA clearance and Japanese regulatory approval in March 2026.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Key Picks
Currently, GEHC carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical Services (WST - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.